Verrica Pharmaceuticals Inc.
VRCA
Rank in Stocks
#21857
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in... Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Share Price
$3.59
Last synced: 2026-11-09
Market Cap
$61.67M
Change (1 day)
12.54%
Change (1 year)
-1.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Verrica Pharmaceuticals Inc. (VRCA)
Category
Healthcare
EPS for Verrica Pharmaceuticals Inc. (VRCA)
EPS as of June 2026 TTM: $-1.74
According to Verrica Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $-1.74. At the end of 2025 the company had an EPS of $-1.68, an increase over its 2024 EPS of $-14.78.
EPS history for Verrica Pharmaceuticals Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.74 | 3.57% |
| 2025 | $-1.68 | -88.63% |
| 2024 | $-14.78 | 0.00% |
| 2023 | $-14.78 | 106.14% |
| 2022 | $-7.17 | -44.72% |
| 2021 | $-12.97 | -24.06% |
| 2020 | $-17.08 | 50.75% |
| 2019 | $-11.33 | 36.34% |
| 2018 | $-8.31 | 118.81% |
| 2017 | $-3.80 | 410.11% |
| 2016 | $-0.74 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,000.00% |
US
|
|
| $-7.07 | 306.32% |
US
|
|
| $-5.29 | 204.02% |
AU
|
|
| $12.88 | -840.24% |
BE
|
|
| $21.56 | -1,339.08% |
NL
|
Questions about Verrica Pharmaceuticals Inc.'s earnings per share (EPS)
What is Verrica Pharmaceuticals Inc.'s earnings per share (EPS)?
Verrica Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $-1.74, as of Jun 2026.
What was Verrica Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Verrica Pharmaceuticals Inc.'s earnings per share (EPS) was $-1.68, compared with $-14.78 in 2024.
How has Verrica Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Verrica Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2025 ($-1.68) and lowest in 2020 ($-17.08).
How does Verrica Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Verrica Pharmaceuticals Inc.'s earnings per share (EPS) ($-1.74) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.